Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.

Source

World

Trump meets Syrian leader in Saudi Arabia the day after announcing end of U.S. sanctions

May 14, 2025

The leader of Syria’s Islamist Hayat Tahrir al-Sham (HTS) group that headed a lightning rebel offensive snatching Damascus from government control, Abu Mohammed al-Jolani, addresses a crowd at the capital’s landmark Umayyad Mosque on December 8, 2024. Abdulaziz Ketaz | Afp | Getty Images U.S. President Donald Trump met with Syrian leader Ahmed al-Sharaa in […]

World

CNBC’s The China Connection newsletter: U.S.-China relations have changed

May 14, 2025

The U.S. and China flags stand behind a microphone at the U.S. Embassy in Beijing on April 9, 2009. Frederic J. Brown | AFP | Getty Images This report is from this week’s CNBC’s The China Connection newsletter, which brings you insights and analysis on what’s driving the world’s second-largest economy. Each week, we’ll explore […]

World

Embattled Burberry to cut 1,700 jobs amid turnaround

May 14, 2025

An Equestrian Knight Device logo on a flag outside the Burberry Group Plc luxury boutique in London, UK, on Tuesday, May 13, 2025. Bloomberg | Getty Images Burberry on Wednesday announced a slew of organizational changes, amid continued turnaround efforts at the embattled luxury house. The company said the measures could lead to a “reduction […]